Biotech Startups

Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.

2 investors

Trias is a biotech company applying circadian biology — how the body's internal clock affects infection and drug response — to research and development. The company studies clock-gene effects on virus replication and parasite transmission.

2 investors

Trince is a Ghent University spin-off developing photoporation technology for physical transfection of cells as an alternative to viral vectors and electroporation. Its technology, including the Lumipore platform, targets R&D, manufacturing, and GMP-compliant clinical applications such as cell and gene therapy.

2 investors

Trioar is a platform company developing next-generation antibody-based technologies to improve the efficacy and therapeutic index of antibody-based therapeutics, including enhanced ADC (antibody-drug conjugate) options. The company focuses on immuno-oncology and cell-targeting therapies for patients with tumors.

2 investors

TriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.

2 investors

Trisk Bio develops scalable preclinical manufacturing processes for AAV (adeno-associated virus) gene therapies, offering bespoke production, purification, and process optimization services. It serves gene therapy developers and preclinical research teams in the biotech industry.

2 investors

Triton Therapeutics is a clinical-stage biotechnology company developing first-in-class medicines for autoimmune and fibrotic diseases.

2 investors

SPT Labtech designs and manufactures laboratory instruments and automation tools for life science research, including liquid handling systems, cryo-electron microscopy sample preparation, and automated sample storage. Its products serve scientists and researchers in genomics, protein crystallization, drug discovery, and next generation sequencing.

2 investors

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in a Phase 2 trial for hepatocellular carcinoma, and TTI-109, a phosphate prodrug of TTI-101.

2 investors

Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.

2 investors

Developing a gene writing system to cure genetic diseases.

2 investors

U-Ploid develops therapeutic treatments to address age-related infertility by preventing chromosome errors in eggs during IVF procedures. The company targets individuals and healthcare providers seeking effective reproductive health solutions for later-life family planning.

2 investors

UniFAHS develops bacteriophage-based products and services to control bacterial contamination and antimicrobial resistance across the food supply chain, serving the poultry, dairy, aquaculture, feed, and food processing sectors. It maintains a phage collection targeting pathogens such as Salmonella, E. coli, Listeria, and Vibrio, and offers a customized phage platform including phage banking, contract research and manufacturing, lab services, and phage-based detection tests.

2 investors

Unveil Instruments develops LightWeigh, a compact interferometric microscope for characterizing nanoparticles (20-300nm) including AAVs, lentiviruses, LNPs, and extracellular vesicles at single-particle level, serving gene therapy and biotech production teams.

2 investors

Uute Scientific is a microbiome science company, spun out of research at the University of Helsinki and Tampere University, that develops a nature-derived microbial ingredient intended to reduce the risk of immune-mediated and autoimmune diseases. It supplies this ingredient to companies seeking to add microbial-diversity health benefits to their products.

2 investors

Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.

2 investors

VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.

2 investors

Valence Labs is an AI research engine that develops computational models to predict cellular responses to genetic and chemical interventions for drug discovery. The company focuses on building virtual cells to accelerate the identification of effective therapeutics.

2 investors

2 investors

Validfor provides computerized system validation (CSV) software and consulting for the life sciences and pharmaceutical industry, covering validation management, data integrity, and quality assurance. It serves regulated companies needing to demonstrate compliance of their computerized systems.

2 investors

Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications. Its work builds on glycobiology and bioorthogonal chemistry research.

2 investors

Valorize Bioscience uses a patented process to modify the color, taste, aroma, and texture of insect proteins while preserving their nutritional content, addressing sensory limitations that have restricted their use. The company aims to broaden the range of consumable product applications for insect-based proteins.

2 investors

VascVersa develops a platform for vascular stem cell therapy and cell therapy manufacturing, serving the advanced therapies and clinical development sectors in vascular biology.

2 investors

2 investors